The sources of TSH, which was excessively released by sulpiride (dopamine D2 receptor antagonist), were studied in 15 female patients with PRL-secreting adenoma (18-43 years). Sequential 3-day administration of sulpiride (100 mg, im) was given to 12 patients with prolactinoma and 6 normal female subjects (19-24 years). Patients with prolactinoma showed much greater TSH responses than normal subjects on the first day. However, TSH responses to sulpiride disappeared on the 2nd and 3rd day in both groups. In contrast, plasma PRL responses to the 1st sulpiride administration were smaller in patients with prolactinoma than in normal subjects, and the response disappeared following the 2nd administration in both groups. When TRH (500 \g=m\g, iv) was administered 120 min after the 3rd sulpiride injection, TSH and PRL increments were not different from those before the sulpiride injection in both patients with prolactinoma (N=6) and normal subjects (N=6) Further, combined administration of sulpiride and TRH in 5 patients with prolactinoma clearly enhanced the TSH and PRL responses compared with the single administration of each agent. These results suggest that there may be two readily releasable pituitary TSH and PRL pools, i.e. one dopamine-related and the other TRH-related, in patients with prolactinoma and normal female subjects. It is well known that patients with prolactin-secreting adenoma (prolactinoma) often show rapid and exaggerated TSH responses to administration of dopamine antagonists (1-3). In humans, adminis¬ tration of exogenous dopamine agonists inhibits TSH secretion and administration of dopamine an¬ tagonists stimulates TSH secretion in normal sub¬ jects and primary hypothyroid patients (3,5-7). Therefore, it is possible that hypothalamic dopamine exerts an inhibitory effect on TSH secretion.The degree of TSH response to dopamine antag¬ onists would reflect the degree of hypothalamic do¬ pamine inhibition on thyrotropes (1,8). For these reasons, pituitary portal dopamine concentration in patients with prolactinoma is considered to be elevated by the positive feedback effect of PRL on hypothalamic dopamine neurons (1,2,8,9), al¬ though reduced hypothalamic dopaminergic tone was previously inferred (10,11). At present, it is not clear whether the TSH sources released by dopamine antagonists from thyrotropes are solely dependent on dopamine or also dependent on TRH. To clarify this, we have examined the TSH responses to sequential 3-day administration of sulpiride (dopamine D2 receptor antagonist), to TRH before and after the sulpiride administration, and to combined administration of sulpiride and TRH in patients with micro-and macro-prolactinomas. Similarly, the PRL sources released by sulpiride and TRH were also exam¬ ined. Our results seem to indicate that dopaminerelated and TRH-related pituitary TSH and PRL pools are independently present in both patients with prolactinoma and normal subjects.
Patients and MethodsWe studied 15 patients with untreated prolactinoma, all females, aged 18-43 years, an...